News | November 10, 2010

FDA Gives Update on CT Brain Scan Investigation

November 10, 2010 – The U.S. Food and Drug Administration (FDA) has concluded that radiation over-exposure during computed tomography (CT) scans was due to user error, not the scanner manufacturers. The finding comes after the FDA investigated more than 300 reports of over-exposure during brain perfusion scans.

The scanners involved were manufactured by GE Healthcare and Toshiba America Medical Systems. Inspectors found there were no violations of FDA laws and regulations. The FDA evaluated the specifications for multislice CT scanners and found when they were used properly, they did not result in overexposure. The FDA also reviewed literature that supports that the manufacturer-defined protocols do provide reasonable and appropriate image quality and dose. Investigators said there is no evidence the manufacturers were involved in modifying any of the hospitals’ scanning protocols to cause the overexposures.

However, the investigation did reveal improvements the industry could make to improve the safety of their equipment and reduce the likelihood of overexposures.

In 2009, the FDA began investigating complaints about radiation overexposure of 206 patients at the Cedars-Sinai Medical Center. As of Oct. 26, 2010, the agency is aware of approximately 385 patients from six hospitals who were exposed to excess radiation during CT brain perfusion scans.

The FDA said a typical radiation dose of 0.5 Gy is expected for a CT brain perfusion scan.

The American Association of Physicists in Medicine (AAPM) is working with CT manufacturers to specify exam protocols. This includes specialty exams such as brain perfusion studies, which may require relatively higher doses.

The FDA encouraged CT facilities to review their protocols and make sure that the values displayed on the control panel corresponded to the doses normally associated with the protocol.

Additionally, the FDA said that CT operators should be specifically trained on dose-saving features such as automatic exposure control (AEC) before using them. If the user activates AEC without reviewing and adjusting the associated parameters, the default values could lead to an overexposure.

For more information: www.aapm.org/pubs/CTProtocols, www.fda.gov

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init